ArticleBMC pregnancy and childbirth2026
Effect of hydroxychloroquine on pregnancy outcomes in women with unexplained recurrent pregnancy loss complicated with antinuclear antibody positivity: a multicentre prospective cohort study protocol.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionUnexplained recurrent pregnancy loss (URPL), defined as two or more pregnancy losses without identifiable cause, affects approximately 2% of reproductive-aged women. Antinuclear antibodies (ANA) may disrupt maternal-fetal immune tolerance in URPL, but the prognostic value of ANA titres and effectiveness of immunomodulatory therapies like hydroxychloroquine (HCQ) remain uncertain. This multicentre prospective cohort study aims to establish a multicentre clinical cohort of ANA-positive women with URPL to investigate whether HCQ improves pregnancy outcomes and to examine the relationship between changes in ANA titres during pregnancy and live birth rates. Additionally, mechanistic exploration will use a large-scale autoantibody microarray with bioinformatics analysis.
methodThis multicentre prospective cohort study across three Chinese tertiary hospitals will recruit 720 ANA-positive URPL patients. Participants will receive either low-dose aspirin alone or low-dose aspirin in combination with HCQ, starting two months before conception. Treatment duration depends on ANA titres: discontinued if negative or < 1:80 at 20 weeks; continued if ≥ 1:160 until 38 weeks. Primary outcome is live birth rate. Autoantibody microarrays will compare profiles between 30 ANA-positive and 30 ANA-negative patients and assess HCQ effects. DISCUSSION: This study will provide prospective evidence on the effectiveness of HCQ in improving live birth rates among ANA-positive women with URPL. Findings may inform future therapeutic strategies and contribute to personalized management for this challenging condition. If HCQ demonstrates benefit, it could offer a readily applicable treatment option in clinical settings. Furthermore, autoantibody profiling may uncover mechanistic pathways and biomarker signatures associated with treatment response and pregnancy success.
trial registrationChiCTR2500105183 (registration date 2025-06-30).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.